KZIA · Kazia Therapeutics Limited

Summary

Kazia Therapeutics Limited reported a half-year loss after tax of AUD 12,552,490 for the period ended 31 December 2025, compared to AUD 10,453,811 in the prior period, with cash reserves of AUD 69,459,980 following a US$46.51 million net PIPE financing. The company provided updates on paxalisib clinical progress in breast cancer and regained Nasdaq compliance.

Key takeaways

• Net loss after tax AUD 12,552,490 for half-year ended 31 December 2025 (vs. AUD 10,453,811 at 31 December 2024)
• Cash and cash equivalents AUD 69,459,980 at 31 December 2025
• PIPE private placement on 2 December 2025 raised US$46.51 million net proceeds
• Regained Nasdaq compliance with Listing Rule 5550(b) on 18 December 2025
• Net current asset position AUD 45,612,689 at 31 December 2025
• Paxalisib Phase 1b study in metastatic TNBC reported >50% CTC reduction on 10 July 2025